Physician

Rohan Faria, M.D.

According to 2025 Medicare claims, Rohan Faria, M.D. (NPI: 1265435077) practices hematology/oncology in the Fort Lauderdale-Pompano Beach-Sunrise, FL market, with the plurality of this provider's patient population coming from Broward, FL. This provider's primary affiliated billing organization is ONCOLOGY & HEMATOLOGY ASSOCIATES OF WEST BROWARD, P.A. (NPI: 1962430561; TIN: 65-0753936) and primary practice location at 33065-4038.

Faria's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 549 traditional Medicare patients, billed 146,331 HCPCS/CPT codes, and received $1,723,957 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 3,045 prescription claims across 446 beneficiaries totaling $9,180,969 in drug costs, led by Calquence (Acalabrutinib Maleate). 2020 DME data shows 26 claims. Open Payments data shows 5 records totaling $127. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has declined steadily, from $3,074,680 to $1,723,957. In contrast, Part D prescription costs have moved from a lower plateau to a higher plateau, from $2,248,081 to $9,180,969. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	665	238,932	$3,074,680
2016	747	338,850	$4,015,898
2017	699	428,737	$4,405,966
2018	737	398,436	$4,023,756
2019	664	331,083	$3,875,247
2020	559	291,002	$3,199,671
2021	559	255,431	$3,531,833
2022	547	170,752	$3,083,136
2023	550	171,318	$3,016,343
2024	549	146,331	$1,723,957

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	326	2,607	$2,248,081
2016	339	2,881	$2,423,020
2017	426	3,307	$3,034,444
2018	430	3,000	$3,429,371
2019	445	2,853	$3,513,405
2020	424	2,744	$3,834,245
2021	439	2,725	$5,268,325
2022	462	2,684	$5,717,667
2023	458	2,963	$5,217,817
2024	446	3,045	$9,180,969

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	64	$41,813
2016	N/R	28	$19,741
2017	N/R	12	$1,418
2018	N/R	69	$13,087
2019	N/R	26	$5,035
2020	N/R	26	$4,038
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	347	523	$98
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	361	756	$70
80053	Blood test, comprehensive group of blood chemicals	95	116	$10
36415	Insertion of needle into vein for collection of blood sample	477	2,247	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	472	2,195	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Calquence	Acalabrutinib Maleate	63	1,890	$967,627
Brukinsa	Zanubrutinib	51	1,530	$763,549
Revlimid	Lenalidomide	30	840	$666,122
Lenalidomide	Lenalidomide	36	1,008	$624,133
Jakafi	Ruxolitinib Phosphate	38	1,065	$608,765

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	5	$127	Janssen Biotech, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Rohan Faria, M.D.?

Tedicare shows public-source Medicare data for Rohan Faria, M.D. (NPI 1265435077), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Rohan Faria, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Rohan Faria, M.D.?

Rohan Faria, M.D. is linked to ONCOLOGY & HEMATOLOGY ASSOCIATES OF WEST BROWARD, P.A. (billing NPI 1962430561) in the available physician profile data.

Does Rohan Faria, M.D. have Open Payments data?

Rohan Faria, M.D. has 5 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.